ABT,Abbott agrees to pay $12 mln fine in China price fixing probe SHANGHAI, Aug 7 Abbott Laboratories has agreed to pay a fine amounting to around $12 million, a spokeswoman said in emailed comments on Wednesday, following Chinese investigations into price fixing and anti-competitive practices by foreign baby formula makers. 
AMZN,Amazon's Bezos pays hefty price for Washington PostHow will Amazon's Bezos change The Washington Post?    How will Amazon's Bezos change The Washington Post?   Jeff Bezos has just shown how valuable one-of-a-kind newspaper properties can still be in the United States. |Â How will Amazon's Bezos change The Washington Post?   VideoHow will Amazon's Bezos change The Washington Post?    How will Amazon's Bezos change The Washington Post?    
AIG,AIG extends deadline on sale of $4.8bln aircraft leasing unit-Basis Point HONG KONG, Aug 7 U.S. insurer American International Group Inc has extended the deadline for the sale of its $4.8 billion ILFC aircraft leasing unit to a Chinese consortium to Aug. 31, Basis Point, a Thomson Reuters publication, reported on Wednesday, citing sources. 
AMGN,Amgen close to Onyx takeover, deal possible within week-sourcesDeals of the day -- mergers and acquisitionsUPDATE 3-Amgen deal for Onyx possible within week-sourcesAmgen deal for Onyx possible within week-sources NEW YORK Onyx Pharmaceuticals Inc is close to selling itself to larger rival Amgen Inc as the cancer drugmaker's high stock price has discouraged other companies from making a counteroffer so far, according to three people familiar with the matter.  Amgen deal for Onyx possible within week-sources NEW YORK Onyx Pharmaceuticals Inc is close to selling itself to larger rival Amgen Inc as the cancer drugmaker's high stock price has discouraged other companies from making a counteroffer so far, according to three people familiar with the matter. NEW YORK, Aug 7 Onyx Pharmaceuticals Inc is close to selling itself to larger rival Amgen Inc as the cancer drugmaker's high stock price has discouraged other companies from making a counteroffer so far, according to three people familiar with the matter.Amgen deal for Onyx possible within week-sources NEW YORK Onyx Pharmaceuticals Inc is close to selling itself to larger rival Amgen Inc as the cancer drugmaker's high stock price has discouraged other companies from making a counteroffer so far, according to three people familiar with the matter.   UPDATE 3-Amgen deal for Onyx possible within week-sourcesAmgen deal for Onyx possible within week-sources NEW YORK Onyx Pharmaceuticals Inc is close to selling itself to larger rival Amgen Inc as the cancer drugmaker's high stock price has discouraged other companies from making a counteroffer so far, according to three people familiar with the matter.  Amgen deal for Onyx possible within week-sources NEW YORK Onyx Pharmaceuticals Inc is close to selling itself to larger rival Amgen Inc as the cancer drugmaker's high stock price has discouraged other companies from making a counteroffer so far, according to three people familiar with the matter. NEW YORK, Aug 7 Onyx Pharmaceuticals Inc is close to selling itself to larger rival Amgen Inc as the cancer drugmaker's high stock price has discouraged other companies from making a counteroffer so far, according to three people familiar with the matter.Amgen deal for Onyx possible within week-sources NEW YORK Onyx Pharmaceuticals Inc is close to selling itself to larger rival Amgen Inc as the cancer drugmaker's high stock price has discouraged other companies from making a counteroffer so far, according to three people familiar with the matter.  (Adds Onyx Pharmaceuticals, Telediffusion de France, TPG Capital and others)UPDATE 3-Amgen deal for Onyx possible within week-sourcesAmgen deal for Onyx possible within week-sources NEW YORK Onyx Pharmaceuticals Inc is close to selling itself to larger rival Amgen Inc as the cancer drugmaker's high stock price has discouraged other companies from making a counteroffer so far, according to three people familiar with the matter.  Amgen deal for Onyx possible within week-sources NEW YORK Onyx Pharmaceuticals Inc is close to selling itself to larger rival Amgen Inc as the cancer drugmaker's high stock price has discouraged other companies from making a counteroffer so far, according to three people familiar with the matter. NEW YORK, Aug 7 Onyx Pharmaceuticals Inc is close to selling itself to larger rival Amgen Inc as the cancer drugmaker's high stock price has discouraged other companies from making a counteroffer so far, according to three people familiar with the matter.Amgen deal for Onyx possible within week-sources NEW YORK Onyx Pharmaceuticals Inc is close to selling itself to larger rival Amgen Inc as the cancer drugmaker's high stock price has discouraged other companies from making a counteroffer so far, according to three people familiar with the matter.    Deals of the day -- mergers and acquisitionsUPDATE 3-Amgen deal for Onyx possible within week-sourcesAmgen deal for Onyx possible within week-sources NEW YORK Onyx Pharmaceuticals Inc is close to selling itself to larger rival Amgen Inc as the cancer drugmaker's high stock price has discouraged other companies from making a counteroffer so far, according to three people familiar with the matter.  Amgen deal for Onyx possible within week-sources NEW YORK Onyx Pharmaceuticals Inc is close to selling itself to larger rival Amgen Inc as the cancer drugmaker's high stock price has discouraged other companies from making a counteroffer so far, according to three people familiar with the matter. NEW YORK, Aug 7 Onyx Pharmaceuticals Inc is close to selling itself to larger rival Amgen Inc as the cancer drugmaker's high stock price has discouraged other companies from making a counteroffer so far, according to three people familiar with the matter.Amgen deal for Onyx possible within week-sources NEW YORK Onyx Pharmaceuticals Inc is close to selling itself to larger rival Amgen Inc as the cancer drugmaker's high stock price has discouraged other companies from making a counteroffer so far, according to three people familiar with the matter.   UPDATE 3-Amgen deal for Onyx possible within week-sourcesAmgen deal for Onyx possible within week-sources NEW YORK Onyx Pharmaceuticals Inc is close to selling itself to larger rival Amgen Inc as the cancer drugmaker's high stock price has discouraged other companies from making a counteroffer so far, according to three people familiar with the matter.  Amgen deal for Onyx possible within week-sources NEW YORK Onyx Pharmaceuticals Inc is close to selling itself to larger rival Amgen Inc as the cancer drugmaker's high stock price has discouraged other companies from making a counteroffer so far, according to three people familiar with the matter. NEW YORK, Aug 7 Onyx Pharmaceuticals Inc is close to selling itself to larger rival Amgen Inc as the cancer drugmaker's high stock price has discouraged other companies from making a counteroffer so far, according to three people familiar with the matter.Amgen deal for Onyx possible within week-sources NEW YORK Onyx Pharmaceuticals Inc is close to selling itself to larger rival Amgen Inc as the cancer drugmaker's high stock price has discouraged other companies from making a counteroffer so far, according to three people familiar with the matter.  (Adds Onyx Pharmaceuticals, Telediffusion de France, TPG Capital and others)UPDATE 3-Amgen deal for Onyx possible within week-sourcesAmgen deal for Onyx possible within week-sources NEW YORK Onyx Pharmaceuticals Inc is close to selling itself to larger rival Amgen Inc as the cancer drugmaker's high stock price has discouraged other companies from making a counteroffer so far, according to three people familiar with the matter.  Amgen deal for Onyx possible within week-sources NEW YORK Onyx Pharmaceuticals Inc is close to selling itself to larger rival Amgen Inc as the cancer drugmaker's high stock price has discouraged other companies from making a counteroffer so far, according to three people familiar with the matter. NEW YORK, Aug 7 Onyx Pharmaceuticals Inc is close to selling itself to larger rival Amgen Inc as the cancer drugmaker's high stock price has discouraged other companies from making a counteroffer so far, according to three people familiar with the matter.Amgen deal for Onyx possible within week-sources NEW YORK Onyx Pharmaceuticals Inc is close to selling itself to larger rival Amgen Inc as the cancer drugmaker's high stock price has discouraged other companies from making a counteroffer so far, according to three people familiar with the matter.   NEW YORK, Aug 7 Onyx Pharmaceuticals Inc is close to selling itself to larger rival Amgen Inc after the cancer drugmaker's high stock price discouraged other companies from making a counter offer, according to three people familiar with the matter.Deals of the day -- mergers and acquisitionsUPDATE 3-Amgen deal for Onyx possible within week-sourcesAmgen deal for Onyx possible within week-sources NEW YORK Onyx Pharmaceuticals Inc is close to selling itself to larger rival Amgen Inc as the cancer drugmaker's high stock price has discouraged other companies from making a counteroffer so far, according to three people familiar with the matter.  Amgen deal for Onyx possible within week-sources NEW YORK Onyx Pharmaceuticals Inc is close to selling itself to larger rival Amgen Inc as the cancer drugmaker's high stock price has discouraged other companies from making a counteroffer so far, according to three people familiar with the matter. NEW YORK, Aug 7 Onyx Pharmaceuticals Inc is close to selling itself to larger rival Amgen Inc as the cancer drugmaker's high stock price has discouraged other companies from making a counteroffer so far, according to three people familiar with the matter.Amgen deal for Onyx possible within week-sources NEW YORK Onyx Pharmaceuticals Inc is close to selling itself to larger rival Amgen Inc as the cancer drugmaker's high stock price has discouraged other companies from making a counteroffer so far, according to three people familiar with the matter.   UPDATE 3-Amgen deal for Onyx possible within week-sourcesAmgen deal for Onyx possible within week-sources NEW YORK Onyx Pharmaceuticals Inc is close to selling itself to larger rival Amgen Inc as the cancer drugmaker's high stock price has discouraged other companies from making a counteroffer so far, according to three people familiar with the matter.  Amgen deal for Onyx possible within week-sources NEW YORK Onyx Pharmaceuticals Inc is close to selling itself to larger rival Amgen Inc as the cancer drugmaker's high stock price has discouraged other companies from making a counteroffer so far, according to three people familiar with the matter. NEW YORK, Aug 7 Onyx Pharmaceuticals Inc is close to selling itself to larger rival Amgen Inc as the cancer drugmaker's high stock price has discouraged other companies from making a counteroffer so far, according to three people familiar with the matter.Amgen deal for Onyx possible within week-sources NEW YORK Onyx Pharmaceuticals Inc is close to selling itself to larger rival Amgen Inc as the cancer drugmaker's high stock price has discouraged other companies from making a counteroffer so far, according to three people familiar with the matter.  (Adds Onyx Pharmaceuticals, Telediffusion de France, TPG Capital and others)UPDATE 3-Amgen deal for Onyx possible within week-sourcesAmgen deal for Onyx possible within week-sources NEW YORK Onyx Pharmaceuticals Inc is close to selling itself to larger rival Amgen Inc as the cancer drugmaker's high stock price has discouraged other companies from making a counteroffer so far, according to three people familiar with the matter.  Amgen deal for Onyx possible within week-sources NEW YORK Onyx Pharmaceuticals Inc is close to selling itself to larger rival Amgen Inc as the cancer drugmaker's high stock price has discouraged other companies from making a counteroffer so far, according to three people familiar with the matter. NEW YORK, Aug 7 Onyx Pharmaceuticals Inc is close to selling itself to larger rival Amgen Inc as the cancer drugmaker's high stock price has discouraged other companies from making a counteroffer so far, according to three people familiar with the matter.Amgen deal for Onyx possible within week-sources NEW YORK Onyx Pharmaceuticals Inc is close to selling itself to larger rival Amgen Inc as the cancer drugmaker's high stock price has discouraged other companies from making a counteroffer so far, according to three people familiar with the matter.    
AAPL,South Korean shares fall 1 pct on Samsung Elec slide, Fed uncertainty'Active in drag,' a funky riff for index fund investorsU.S. appeals court revives Apple patent claims vs. Google'Active in drag,' a funky riff for index fund investors NEW YORK As investors pour more and more money into funds that track indexes, the indexes themselves are getting more esoteric.  'Active in drag,' a funky riff for index fund investors NEW YORK As investors pour more and more money into funds that track indexes, the indexes themselves are getting more esoteric. Aug 7 A U.S. appeals court ruled on Wednesday that Apple Inc should be able to renew its arguments at the International Trade Commission that Google Inc's  Motorola Mobility unit violated two patents relating to the iPhone.'Active in drag,' a funky riff for index fund investors NEW YORK As investors pour more and more money into funds that track indexes, the indexes themselves are getting more esoteric.   U.S. appeals court revives Apple patent claims vs. Google'Active in drag,' a funky riff for index fund investors NEW YORK As investors pour more and more money into funds that track indexes, the indexes themselves are getting more esoteric.  'Active in drag,' a funky riff for index fund investors NEW YORK As investors pour more and more money into funds that track indexes, the indexes themselves are getting more esoteric. Aug 7 A U.S. appeals court ruled on Wednesday that Apple Inc should be able to renew its arguments at the International Trade Commission that Google Inc's  Motorola Mobility unit violated two patents relating to the iPhone.'Active in drag,' a funky riff for index fund investors NEW YORK As investors pour more and more money into funds that track indexes, the indexes themselves are getting more esoteric.  NEW YORK, Aug 7 As investors pour more and more money into funds that track indexes, the indexes themselves are getting more esoteric.U.S. appeals court revives Apple patent claims vs. Google'Active in drag,' a funky riff for index fund investors NEW YORK As investors pour more and more money into funds that track indexes, the indexes themselves are getting more esoteric.  'Active in drag,' a funky riff for index fund investors NEW YORK As investors pour more and more money into funds that track indexes, the indexes themselves are getting more esoteric. Aug 7 A U.S. appeals court ruled on Wednesday that Apple Inc should be able to renew its arguments at the International Trade Commission that Google Inc's  Motorola Mobility unit violated two patents relating to the iPhone.'Active in drag,' a funky riff for index fund investors NEW YORK As investors pour more and more money into funds that track indexes, the indexes themselves are getting more esoteric.    'Active in drag,' a funky riff for index fund investorsU.S. appeals court revives Apple patent claims vs. Google'Active in drag,' a funky riff for index fund investors NEW YORK As investors pour more and more money into funds that track indexes, the indexes themselves are getting more esoteric.  'Active in drag,' a funky riff for index fund investors NEW YORK As investors pour more and more money into funds that track indexes, the indexes themselves are getting more esoteric. Aug 7 A U.S. appeals court ruled on Wednesday that Apple Inc should be able to renew its arguments at the International Trade Commission that Google Inc's  Motorola Mobility unit violated two patents relating to the iPhone.'Active in drag,' a funky riff for index fund investors NEW YORK As investors pour more and more money into funds that track indexes, the indexes themselves are getting more esoteric.   U.S. appeals court revives Apple patent claims vs. Google'Active in drag,' a funky riff for index fund investors NEW YORK As investors pour more and more money into funds that track indexes, the indexes themselves are getting more esoteric.  'Active in drag,' a funky riff for index fund investors NEW YORK As investors pour more and more money into funds that track indexes, the indexes themselves are getting more esoteric. Aug 7 A U.S. appeals court ruled on Wednesday that Apple Inc should be able to renew its arguments at the International Trade Commission that Google Inc's  Motorola Mobility unit violated two patents relating to the iPhone.'Active in drag,' a funky riff for index fund investors NEW YORK As investors pour more and more money into funds that track indexes, the indexes themselves are getting more esoteric.  NEW YORK, Aug 7 As investors pour more and more money into funds that track indexes, the indexes themselves are getting more esoteric.U.S. appeals court revives Apple patent claims vs. Google'Active in drag,' a funky riff for index fund investors NEW YORK As investors pour more and more money into funds that track indexes, the indexes themselves are getting more esoteric.  'Active in drag,' a funky riff for index fund investors NEW YORK As investors pour more and more money into funds that track indexes, the indexes themselves are getting more esoteric. Aug 7 A U.S. appeals court ruled on Wednesday that Apple Inc should be able to renew its arguments at the International Trade Commission that Google Inc's  Motorola Mobility unit violated two patents relating to the iPhone.'Active in drag,' a funky riff for index fund investors NEW YORK As investors pour more and more money into funds that track indexes, the indexes themselves are getting more esoteric.   * Shares fall 1 pct as uncertainty grows over Fed tapering'Active in drag,' a funky riff for index fund investorsU.S. appeals court revives Apple patent claims vs. Google'Active in drag,' a funky riff for index fund investors NEW YORK As investors pour more and more money into funds that track indexes, the indexes themselves are getting more esoteric.  'Active in drag,' a funky riff for index fund investors NEW YORK As investors pour more and more money into funds that track indexes, the indexes themselves are getting more esoteric. Aug 7 A U.S. appeals court ruled on Wednesday that Apple Inc should be able to renew its arguments at the International Trade Commission that Google Inc's  Motorola Mobility unit violated two patents relating to the iPhone.'Active in drag,' a funky riff for index fund investors NEW YORK As investors pour more and more money into funds that track indexes, the indexes themselves are getting more esoteric.   U.S. appeals court revives Apple patent claims vs. Google'Active in drag,' a funky riff for index fund investors NEW YORK As investors pour more and more money into funds that track indexes, the indexes themselves are getting more esoteric.  'Active in drag,' a funky riff for index fund investors NEW YORK As investors pour more and more money into funds that track indexes, the indexes themselves are getting more esoteric. Aug 7 A U.S. appeals court ruled on Wednesday that Apple Inc should be able to renew its arguments at the International Trade Commission that Google Inc's  Motorola Mobility unit violated two patents relating to the iPhone.'Active in drag,' a funky riff for index fund investors NEW YORK As investors pour more and more money into funds that track indexes, the indexes themselves are getting more esoteric.  NEW YORK, Aug 7 As investors pour more and more money into funds that track indexes, the indexes themselves are getting more esoteric.U.S. appeals court revives Apple patent claims vs. Google'Active in drag,' a funky riff for index fund investors NEW YORK As investors pour more and more money into funds that track indexes, the indexes themselves are getting more esoteric.  'Active in drag,' a funky riff for index fund investors NEW YORK As investors pour more and more money into funds that track indexes, the indexes themselves are getting more esoteric. Aug 7 A U.S. appeals court ruled on Wednesday that Apple Inc should be able to renew its arguments at the International Trade Commission that Google Inc's  Motorola Mobility unit violated two patents relating to the iPhone.'Active in drag,' a funky riff for index fund investors NEW YORK As investors pour more and more money into funds that track indexes, the indexes themselves are getting more esoteric.    
